Our results indicate that in NSCLC cells treated with platinum-based chemotherapeutic agents, S100A11 silencing leads to higher PLA2 activity that drives enhanced mitochondrial superoxide production, which results in potentiation of apoptosis. Here, S100A11 is linked to non-small cell lung carcinoma.